Literature DB >> 2189012

A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria.

T M Davis1, W Supanaranond, S Pukrittayakamee, J Karbwang, P Molunto, S Mekthon, N J White.   

Abstract

Recommended initial treatment of severe chloroquine-resistant falciparum malaria consists of a 4-h loading infusion of 20 mg of quinine dihydrochloride (salt)/kg of body weight. To achieve and maintain therapeutic blood quinine concentrations (10 mg/l) safely and rapidly, a consecutive-infusion regimen (7 mg of salt/kg of body weight over 30 min followed by 10 mg of salt/kg of body weight over 4 h) based on pharmacokinetic parameters in cerebral malaria has been suggested. This regimen was evaluated in 16 adults (6 male, 10 female; mean age, 25.9 years) with severe falciparum malaria. Plasma quinine concentrations (mean +/- SE) were 8.7 +/- 1.2 mg/l at 30 min and 11.0 +/- 1.8 mg/l at 4.5 h. There was no electrocardiographic evidence of serious cardiotoxicity during the 4.5-h infusion period, and systolic blood pressure fell by greater than 10 mm Hg in only one patient. Parasite clearance in 13 surviving patients (median count on admission, 438 x 10(3)/microliters; range, 500-122 x 10(4) took an average of 71 h (range, 9-115). This regimen is safe, effective, and suitable for use in an intensive care unit.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189012     DOI: 10.1093/infdis/161.6.1305

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 2.  Cerebral malaria.

Authors:  C R Newton; T T Hien; N White
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

3.  Effect of dose size on the pharmacokinetics of orally administered quinine.

Authors:  A Sowunmi; L A Salako
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.

Authors:  J Karbwang; T M Davis; S Looareesuwan; P Molunto; D Bunnag; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

Review 5.  Diagnosis and treatment of malaria in Britain.

Authors:  M Molyneux; R Fox
Journal:  BMJ       Date:  1993-05-01

Review 6.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

7.  Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by Plasmodium falciparum.

Authors:  M Le Jouan; V Jullien; E Tetanye; A Tran; E Rey; J-M Tréluyer; M Tod; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

8.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 9.  Adverse effects of antimalarials. An update.

Authors:  G A Luzzi; T E Peto
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 10.  High first dose quinine regimen for treating severe malaria.

Authors:  A Lesi; M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.